Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

Eye Condition a ‘Very Rare’ Side Effect of Semaglutide, EMA Says

News Daily News

Eye Condition a ‘Very Rare’ Side Effect of Semaglutide, EMA Says

June 06, 2025

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

News Conference News European Congress on Obesity 2025

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

Michael O'Riordan

May 13, 2025

GLP-1 Drugs in Diabetes Don’t Raise Suicidality Risk, New Data Confirm

News Daily News

GLP-1 Drugs in Diabetes Don’t Raise Suicidality Risk, New Data Confirm

February 26, 2025

European Medicines Agency Investigating GLP-1 Drugs and Eye Disease

News Daily News

European Medicines Agency Investigating GLP-1 Drugs and Eye Disease

January 21, 2025

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

News Daily News

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

October 23, 2024

‘Disproportionate’ Suicide/Self-Harm Signal With Semaglutide: WHO Database

News Daily News

‘Disproportionate’ Suicide/Self-Harm Signal With Semaglutide: WHO Database

Michael O'Riordan

August 21, 2024

EMA: No Evidence of Link Between GLP-1 Receptor Agonists and Suicidal Thoughts

News Daily News

EMA: No Evidence of Link Between GLP-1 Receptor Agonists and Suicidal Thoughts

April 12, 2024

Injectable Semaglutide Shortage Forces Physicians to Pivot

News Daily News

Injectable Semaglutide Shortage Forces Physicians to Pivot

February 05, 2024

FDA: No Signs of Link Between GLP-1s and Suicidal Thoughts, Actions

News Daily News

FDA: No Signs of Link Between GLP-1s and Suicidal Thoughts, Actions

January 12, 2024

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

News Daily News

Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes

Michael O'Riordan

December 08, 2023

GLP-1 Meds Linked to 265 Reports to FDA of Suicidal Ideation: Reuters

News Daily News

GLP-1 Meds Linked to 265 Reports to FDA of Suicidal Ideation: Reuters

September 28, 2023

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

News Daily News

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

Michael O'Riordan

September 15, 2023

EMA Investigating Suicidal Thinking With GLP-1 Drugs for Weight Loss

News Daily News

EMA Investigating Suicidal Thinking With GLP-1 Drugs for Weight Loss

Michael O'Riordan

July 12, 2023

Two New Studies Highlight Lack of Diversity in Cardiovascular RCTs

News Daily News

Two New Studies Highlight Lack of Diversity in Cardiovascular RCTs

Michael O'Riordan

July 11, 2023

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

Finerenone Cuts CV Events in CKD Patients With Diabetes: FIGARO-DKD

News Daily News

Finerenone Cuts CV Events in CKD Patients With Diabetes: FIGARO-DKD

Michael O'Riordan

May 11, 2021

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

News Daily News

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

February 07, 2020

TCTMD’s Top 10 Most Popular Stories for August 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2018

September 04, 2018

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

News Conference News EAS 2018

Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics

Yael L. Maxwell

May 16, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.